



August 16, 2013

AnGes MG, Inc.

The Current Situation of AnGes

AnGes MG Inc. ("AnGes") apologizes to our shareholders and stakeholders for the concern the Company's current situation has caused due to the announcement of the results of Phase 3 Trial of Allovectin®.

1. About Allovectin®

Vical, Inc. ("Vical") in the US announced that the Allovectin® Phase 3 trial failed to demonstrate a statistically significant improvement in both the primary and secondary efficacy endpoints. AnGes MG Group will thoroughly examine the detailed Phase 3 trial data of Allovectin® which will be sent to the Company to review the application of Allovectin® to cancers other than melanoma.

2. About financial condition and "key events concerning going concern assumption"

The Group worked to reduce costs mainly through management rationalization and procured funds (2,565 million yen by allocating new shares to third party and by exercising share warrants with amended exercise price for the six months period ended June 2013 and 830 million yen in July, totaling 3,395 million yen).

As a result, the Group became financially stable to promote its major research and development activities for the time being. Therefore, the "key events concerning going concern assumption" has been eliminated in the second quarter report.

3. About further responses to the Company's projects

Due to these circumstances, AnGes MG will focus on its Collatogene Phase 3 trial in the US, NF-kB decoy oligo related trials and the development of CIN therapeutic vaccine.

###

Disclaimer: This is a translation of the news release posted in Japanese. In case of any deviations between the two language versions, the original document in Japanese shall take precedence.

<p>AnGes MG, Inc. Corporate Communications TEL:+81-3-5730-2641, FAX:+81-3-5730-2635 http://www.anges-mg.com Email:info@anges-mg.com</p>
--